Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Colorectal Cancer
In brief
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying surgery and thalidomide to see how well they work compared to surgery alone in treating patients with recurrent or metastatic colorectal cancer.
Key facts
- Study ID
- NCT00019747
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 39
- Starts
- 1999-08-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2015-10-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Center for Cancer Care at Goshen Health System — Goshen, Indiana, United States
- Suburban Hospital Cancer Program — Bethesda, Maryland, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
- Charles M. Barrett Cancer Center at University Hospital — Cincinnati, Ohio, United States
- UPMC Cancer Center at UPMC Presbyterian — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.